Data / Form D filings / Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.: Form D filing
Nuvectis Pharma, Inc., a biotechnology company in Fort Lee, NJ, filed a Form D with the SEC in 2022. The latest, on August 10, 2022, reports $15.9 million sold of a $15.9 million offering to 19 investors.
Find out what Nuvectis Pharma, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1 BRIDGE PLAZA, SUITE 275, Fort Lee, NJ, 07024
- Phone
- (201) 614-3150
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1875558
The full lists. Form D filings in New Jersey: 714 rows, $35.70, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 10, 2022 | New notice | $15,878,637 | $15,878,637 | $0 | 19 | Jul 27, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James Oliviero | Director | |
| Enrique Poradosu | Executive Officer | |
| Matthew Kaplan | Director | |
| Michael Carson | Executive Officer | |
| Kenneth Hoberman | Director | |
| Ron Bentsur | Executive Officer, Director | |
| Shay Shemesh | Executive Officer |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
Every Form D from the week of Aug 8, 2022 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Nuvectis Pharma, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.